INCREASE INCIDENCE OF KAWASAKI DISEASE SOMETIMES WITH BCG SCAR REACTIVATION DURING CORONA PANDEMIC
Keywords:
KD(Kawasaki Disease), IKD(Incomplete Kawasaki Disease), BCG Scar, COVID 19, IVIG, AspirinAbstract
Kawasaki disease is an acute vasculitis of childhood. The disease was described in Japan in 1967 by Dr. Tomasaku Kawasaki(1).
The etiology of KD remains unknown despite extensive research. Many of the clinical features resemble with childhood exanthematous infection with fever lead to the investigation of many infectious agent as etiological factor of Kawasaki Disease. It is observed that the ongoing Covid 19 Pandemic is associated with an increase incidence of Kawasaki Disease. At the end of April 2020 and the begining of may 2020 we identified a higher number of Kawasaki disease cases, some of them with BCGitis that was related to Covid 19 Epidemic in West Bengal ,starting 4 to 6 week of the disease. Similar observation was also reported from different part the World including India. Interpretation of my observation suggest that Human Corona Virus would be related to KD/IKD and that may thrown light to the treatment of Covid 19 disease at least in Pediatric population.
Aim of Study: The aim of this study is along with increase incidence of KD/IKD with BCG Scar reactivation ,What are the relation of pathophysiological process and treatment of both the condition. I retrospectively considered the patient attended at my OPD since July 2019 to July 2020. The Patient diagnosed as KD/IKD before the epidemic and during this period are compared. It is found that the incidence of KD/IKD increase during Covid 19 Pandemic situation. The child who were diagnosed as the KD/IKD, referred to Pediatric Hospital for better management.
References
I. Rudolph’s Pediatrics 23rd edition page 2283-2288
II. The Epidemiology and Pathogenesis of Kawasaki Disease Anne H. Rowley and Stanford. T. Shulman. Pediater, 11th December 2018 https://doi.org/10.3389/fped.2018.00374
III. Virology Connect Mayo Clinic. Jinmeng Sun, et.al. https://nurture.virologyconnect.com
IV. Pub.med-“C” reactive protein level in the early stage of Covid-19 L Wang med mal infect 2020,January
V. Blood thinners as a treatment for COVID 19. What the Science says and what it means for you.May19, 2020. Karmeinz Peter et al.
VI. Burns Jc, Glode MP.Kawasaki Syndrome Lancet 2004;364 (533-44).
VII. Measles infection causing BCG reactivation: A case report. Sobana Muthuvelu.et.al.BMC Pediatrics.19.Article number 251(2019).
VIII. Inflammatory process in Kawasaki Disease reach their peak at the sixth day of fever onset.Laboratory profile according to duration of fever.Kyung Yil Lee et al.JKMS.
IX. Rudlophs’s Pediatrics.23rd ed.
X. The Novel Human Coronaviruses NL63 and HKU1.Krzysztof Pyrc et al. American Society for Microbiology 2007.Journal of Virology.
XI. The Role of a Novel Coronavirus In Kawasaki Disease.Khan.Jeffrey S. Yale University,New Haven.CT,United States.2006.
XII. The Immunomodulatory effect of intravenous immunoglobulin therapy in KD. JC.Burns et al.Expert review of clinical immunology.2015;11(7):819-825.
XIII. Role of intravenous immunoglobulin in the treatment of Kawasaki Disease. Mindy S .Lo.,Jane W.Newburger.05 December 2017. https://doi.org/1-.1111/1756-185x.13220
XIV. Acetylsalicylic acid for children with Kawasaki disease Teeranai Sakulchit,et al .Canadian Family Physician.2017Aug;63(8):607-609.
XV. Diagnosis ,Treatment ,and Long Term Management of Kawasaki Disease:A Scientific Statement for Health Professionals Forms the American Heart Association Brain W.McCrindle et al 29 Mar 2017;135:e927-e999 https://doi.org/10.1161/CIR.0000000000000484
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.